Last reviewed · How we verify

Patiromer Oral Product

Wake Forest University Health Sciences · FDA-approved active Small molecule

Patiromer Oral Product is a Potassium binder Small molecule drug developed by Wake Forest University Health Sciences. It is currently FDA-approved for Hyperkalemia in patients with chronic kidney disease or heart failure on renin-angiotensin-aldosterone system inhibitors. Also known as: Valtressa.

Patiromer is a non-absorbed potassium binder that sequesters potassium in the gastrointestinal tract to reduce serum potassium levels.

Patiromer is a non-absorbed potassium binder that exchanges sodium for potassium in the gastrointestinal tract, reducing serum potassium levels. Used for Hyperkalemia (elevated serum potassium levels).

At a glance

Generic namePatiromer Oral Product
Also known asValtressa
SponsorWake Forest University Health Sciences
Drug classPotassium binder
TargetPotassium ion (K+) in gastrointestinal lumen
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Patiromer is a cation exchange polymer that binds potassium ions in the colon through ionic interactions, preventing potassium reabsorption and increasing fecal potassium excretion. This mechanism allows for reduction of hyperkalemia without systemic absorption, making it suitable for chronic management of elevated serum potassium levels in patients taking medications that increase potassium retention.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Patiromer Oral Product

What is Patiromer Oral Product?

Patiromer Oral Product is a Potassium binder drug developed by Wake Forest University Health Sciences, indicated for Hyperkalemia in patients with chronic kidney disease or heart failure on renin-angiotensin-aldosterone system inhibitors.

How does Patiromer Oral Product work?

Patiromer is a non-absorbed potassium binder that sequesters potassium in the gastrointestinal tract to reduce serum potassium levels.

What is Patiromer Oral Product used for?

Patiromer Oral Product is indicated for Hyperkalemia in patients with chronic kidney disease or heart failure on renin-angiotensin-aldosterone system inhibitors.

Who makes Patiromer Oral Product?

Patiromer Oral Product is developed and marketed by Wake Forest University Health Sciences (see full Wake Forest University Health Sciences pipeline at /company/wake-forest-university-health-sciences).

Is Patiromer Oral Product also known as anything else?

Patiromer Oral Product is also known as Valtressa.

What drug class is Patiromer Oral Product in?

Patiromer Oral Product belongs to the Potassium binder class. See all Potassium binder drugs at /class/potassium-binder.

What development phase is Patiromer Oral Product in?

Patiromer Oral Product is FDA-approved (marketed).

What are the side effects of Patiromer Oral Product?

Common side effects of Patiromer Oral Product include Hypomagnesemia, Constipation, Nausea, Abdominal discomfort.

What does Patiromer Oral Product target?

Patiromer Oral Product targets Potassium ion (K+) in gastrointestinal lumen and is a Potassium binder.

Related